• UCLA Health
  • myUCLAhealth
  • School of Medicine
Institute of Urologic Oncology

UCLA Institute of Urologic Oncology

Institute of Urologic Oncology
  • About Us
    • Director's Welcome
    • Board of Directors
    • IUO in the News
    • Why Choose the UCLA IUO
    • Support the IUO
    • Contact Us
    • The Wasserman Building
    • Maps and Directions
    • IUO Membership Information
    • Administrative & Research Staff
    • Positions Available
  • Clinical Programs
    • Bladder Cancer
    • Kidney Cancer
    • Prostate Cancer
    • Testicular Cancer
    • Integrated Cancer Program
    • Cancer Genetic Risk Assessment Program
    • Second Opinion for Cancer
  • Research Programs
    • Clinical Trials
    • Faculty Labs
    • Bladder Cancer
    • Kidney Cancer
    • Prostate Cancer
    • PSMA Risk Calculator
    • SPORE In Prostate Cancer
    • External Funding Opportunities
    • Webinars / Videos
  • Clinical Trials
    • What Is a Clinical Trial?
    • Who Should Consider Clinical Trials & Why
    • Bladder Cancer Clinical Trials
    • Kidney Cancer Clinical Trials
    • Prostate Cancer Clinical Trials
    • Clinical Research Team
    • IUO Membership Study Information
  • For Patients
    • Contact Us
    • Clinical Updates
    • Health Plans and Financial Matters
    • Maps and Directions
    • myUCLAhealth
    • Patient Testimonials
    • Preparing for Surgery
    • Webinars / Videos
  • Fellowship
    • Current Fellows
    • Former Fellows
    • Fellow Testimonials
    • UCLA Health Aerial Tour
  • For Healthcare Professionals
    • How to Refer a Patient
    • Lectures & Conferences
    • CTSI Distinguished Speaker Seminar Series
    • DGSOM Research Seminars
    • DGSOM Events
    • JCCC Seminars
    • SPORE Lectures
    • External Funding Opportunities
  • Expert Team
    • Board of Directors
    • Medical Oncology
    • Nuclear Medicine
    • Pathology
    • Radiation Oncology
    • Radiology
    • Urologic Oncology
    • Research Faculty
    • Emeritus Faculty
  • UCLA Health
  • myUCLAhealth
  • School of Medicine

UCLA Institute of Urologic Oncology

Clinical Trials

Clinical Trials

Clinical Trials

  • What Is a Clinical Trial?
  • Who Should Consider Clinical Trials & Why
  • Bladder Cancer Clinical Trials
  • Kidney Cancer Clinical Trials
  • Prostate Cancer Clinical Trials
  • Clinical Research Team
  • IUO Membership Study Information
  • What Is a Clinical Trial?
  • Who Should Consider Clinical Trials & Why
  • Bladder Cancer Clinical Trials
  • Kidney Cancer Clinical Trials
  • Prostate Cancer Clinical Trials
  • Clinical Research Team
  • IUO Membership Study Information
  1. Home
  2. Institute of Urologic Oncology
  3. Clinical Trials
  4. BMS Checkmate: A Study for Kidney Cancer Patients after Nephrectomy

BMS Checkmate: A Study for Kidney Cancer Patients after Nephrectomy

Share this

Lay title: BMS Checkmate: A Study for Kidney Cancer Patients after Nephrectomy

Technical Title: A Phase 3 Randomized, Double-Blind Study of Nivolumab Monotherapy or Nivolumab Combined with Ipilimumab Combination vs Placebo in Participants with Localized Renal Cell Carcinoma Who Underwent Radical or Partial Nephrectomy and Who Are at High Risk of Relapse

Disease Type: Patients with renal cell carcinoma (a type of kidney cancer) who are planned to have a nephrectomy (surgical removal of the kidney)

Basic information: The purpose of this study is to compare the effectiveness, safety, and tolerability of an investigational drug combination in patients with localized kidney cancer that have had their tumors completely removed, but are at risk of having their cancer return. The drug combination includes two drugs: nivolumab (also known as OPDIVO) and ipilimumab (also known as Yervoy).

Nivolumab and ipilimumab are types of immunotherapy. Immunotherapy works by encouraging the body's own immune system to attack the cancer cells. Nivolumab is approved for the treatment of certain types of cancer, including skin, kidney, blood, and lung. Ipilimumab is approved for the treatment of metastatic melanoma. The combination of nivolumab and ipilimumab is also approved for the treatment of advanced kidney cancer that has spread to other parts of the body and metastatic melanoma.

The study has two parts. In Part A, patients will be randomized to one of two groups: (1) receive combination of nivolumab and ipilimumab, or (2) receive placebo.

In Part B, patients will randomized to one of three groups: (1) receive combination of nivolumab and ipilimumab, (2) receive placebo, or (3) receive nivolumab alone.

The study is blinded, which means that neither you nor your study doctor will know which study treatment you are receiving.

Research Procedures (not a complete list):
You will return to clinic every 2 weeks to receive study medication and complete study procedures. Procedures include questionnaires, a physical exam, blood test, and assessment of side effects. You will come to clinic for up to 12 cycles, or 6 months.

Eligibility Criteria (Not a complete list):
Inclusion Criteria:

  • Diagnosis of renal cell carcinoma with mostly clear cell histology
  • Nephrectomy within 4-12 weeks of first study treatment
  • Able to provide 10-20 unstained kidney tumor slides, preferably from nephrectomy

Exclusion Criteria:

  • No metastases
  • No diagnosis of hepatitis B, hepatitis C, or HIV
  • No prior treatment with anti-PD-1, anti-PD-L1m anti-PD-L2, or anti-CTLA-4 antibodies
  • No prior systemic anti-cancer treatment (such as chemotherapy) for kidney cancer

For More Detailed Information, Contact:

  • Brian Shuch, MD, Principal Investigator, Associate Professor of UCLA Urology
  • Sara R., Study Coordinator, (310) 794-2877

Read more about this study (NCT03138512) on ClinicalTrials.gov.

Like Us on Facebook Follow Us on Twitter Subscribe to Our Videos on YouTube Follow us on Instagram Connect with Us on LinkedIn Follow us on Pinterest
UCLA Health hospitals ranked best hospitals by U.S. News & World Report
  • UCLA Health
  • Find a Doctor
  • School of Medicine
  • School of Nursing
  • UCLA Campus
  • Directory
  • Newsroom
  • Subscribe
  • Patient Stories
  • Giving
  • Careers
  • Volunteer
  • International Services
  • Privacy Practices
  • Nondiscrimination
  • Billing
  • Health Plans
  • Emergency
  • Report Broken Links
  • Terms of Use
  • 1-310-825-2631
  • Maps & Directions
  • Contact Us
  • Your Feedback
  • Report Misconduct
  • Get Social
  • Sitemap
Like Us on Facebook Follow Us on Twitter Subscribe to Our Videos on YouTube Follow us on Instagram Connect with Us on LinkedIn Follow us on Pinterest